The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized multicenter phase Ib/II study of neoadjuvant chemoradiation therapy (CRT) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic cancer.
 
Osama E. Rahma
Employment - Outcomes4me
Leadership - Outcomes4me
Honoraria - Alaunus Global; Clinical Care Options; Leerink; Merck; MI Bioresearch; PRMA Consulting
Consulting or Advisory Role - Alcimed; Bayer; Celgene; Defined Health; Five Prime Therapeutics; Genentech; Gfk; GlaxoSmithKline; Imvax; Leerink; Leerink; Maverick Therapeutics; Merck; PureTech; Putnam Associates; Sobi
Research Funding - Amgen (Inst); Merck
Patents, Royalties, Other Intellectual Property - PD-1/PD-L1 (Inst); Pending patent (DFCI 2386.010) (Inst)
Travel, Accommodations, Expenses - Clinical Care Options; Genentech; Merck; PRMA Consulting; PureTech
 
Matthew H. G. Katz
Consulting or Advisory Role - Abbvie; Abbvie; Abbvie; Alcresta Therapeutics
 
Brian M. Wolpin
Honoraria - Celgene; G1 Therapeutics
Consulting or Advisory Role - BioLineRx; Celgene; G1 Therapeutics; Genentech; GRAIL; GRAIL
Research Funding - Celgene; Lilly
 
Andressa Dias-Costa
No Relationships to Disclose
 
Jonathan Nowak
No Relationships to Disclose
 
Scott J. Rodig
Leadership - Immunitas
Stock and Other Ownership Interests - Immunitas
Honoraria - Bristol-Myers Squibb; Perkin Elmer
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Affimed Therapeutics; Bristol-Myers Squibb; Kite, a Gilead company; Merck
Patents, Royalties, Other Intellectual Property - Patent pending for use of Anti-galectin1 antibodies for diagnostic use.
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche
 
Stephanie Dougan
Leadership - Kojin Therapeutics; Neoleukin Therapeutics (I)
Stock and Other Ownership Interests - Kojin Therapeutics
Consulting or Advisory Role - GlaxoSmithKline
Research Funding - Bristol-Myers Squibb; Lilly; Novartis Institutes for BioMedical Research
Patents, Royalties, Other Intellectual Property - Patent pending for an HSV immunotherapeutic delivery vector
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen (Inst); AstraZeneca; Bayer (Inst); BeiGene; Boehringer Ingelheim; Celularity; Daiichi Sankyo/UCB Japan; Eisai; Eisai; Exact Sciences; Foundation Medicine; Immuneering; Incyte (Inst); Ipsen (Inst); Janssen; Lilly (Inst); Natera; Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); SOBI; Treos Bio
Patents, Royalties, Other Intellectual Property - Patent WO/2018/183488; Patent WO/2019/055687
Other Relationship - AstraZeneca; Exelixis; Lilly; Merck (Inst); Pancreatic Cancer Action Network
 
Chee-Chee H. Stucky
No Relationships to Disclose
 
Rawad Elias
No Relationships to Disclose
 
Gina R. Petroni
Research Funding - Merck
 
Todd W. Bauer
Stock and Other Ownership Interests - ZielBio
 
Craig L. Slingluff
Consulting or Advisory Role - CureVac; Immatics (Inst); Polynoma (Inst)
Research Funding - 3M (Inst); Celldex (Inst); GlaxoSmithKline (Inst); Merck Sharp & Dohme (Inst); Theraclion (Inst)
Patents, Royalties, Other Intellectual Property - Licensing and Ventures Group of the University of Virginia
Travel, Accommodations, Expenses - Polynoma
(OPTIONAL) Uncompensated Relationships - agenus (Inst)